A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

作者: YueWang, YaxianMei, ZhenghongAo, YuanzhiChen, YichaoJiang, XiaoqingChen, RuoyaoQi, BaorongFu, JixianTang, MujinFang, MinYou, TianyingZhang, QuanYuan, WenxinLuo, NingshaoXia
杂志: Antiviral Research
Doi: https://www.doi.org/10.1016/j.antiviral.2022.105265
出版日期: 2022 Mar

论文中使用的产品/服务

Quotation shows PackGene:C57BL/6 mice (Shanghai SLAC Laboratory Animal Co., Ltd., China) were injected with HBV/adeno-associated virus (AAV) (HBV–B from PackGene Biotech, HBV-D from Five Plus Molecular Medicine Institute, China) via the caudal vein. HCAb treatment was conducted as previously described

Research Field:liver

AAV Serotype:HBV–B

Animal or cell line strain:C57BL/6 mice

询价

摘要

Sustainable viral suppression with hepatitis B surface antigen (HBsAg) loss is the new treatment goal for chronic hepatitis B (CHB). The role of antibodies in therapies for persistent hepatitis B virus (HBV) infection has received constant attention. While immunotherapy holds great promise, challenges for the antibody-based prevention and control of HBV in CHB include broad HBV antigenic diversity and the need for long-term viral suppression. In this study, we identified a new anti-HBsAg nanobody (Nb), 125s, isolated from HBsAg-immunized alpaca and confirmed its excellent potency in HBsAg clearance and broad-spectrum therapeutic activity against three HBV subtypes in vivo. In addition, we characterized a novel epitope at the C-terminus of the HBsAg surface motif from amino acids 157 to 174. A 125s-based long-term passive immunization program was efficacious at HBsAg clearance and inducing cellular immune responses, offering a promising outlook for CHB immunotherapy.

文章链接

关于派真

作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。

凭借我们独立知识产权的π-alpha^TM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。